JPH11505724A - 生物活性ペプチド及び核酸の同定方法 - Google Patents

生物活性ペプチド及び核酸の同定方法

Info

Publication number
JPH11505724A
JPH11505724A JP8536119A JP53611996A JPH11505724A JP H11505724 A JPH11505724 A JP H11505724A JP 8536119 A JP8536119 A JP 8536119A JP 53611996 A JP53611996 A JP 53611996A JP H11505724 A JPH11505724 A JP H11505724A
Authority
JP
Japan
Prior art keywords
peptide
random
cells
vector
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP8536119A
Other languages
English (en)
Japanese (ja)
Inventor
イェンセン、マルティン・ローランド
ペデルセン、フィン・スコウ
モウリツセン、ソレン
ヒンデルソン、ペーター
ドゥーフ、モーゲンス
ソレンセン、ミヒャエル・シャンドルフ
ダルム、イベン
ルンド、アンデルス・ヘンリック
Original Assignee
エム・アンド・イー・バイオテク・エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8095753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH11505724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エム・アンド・イー・バイオテク・エー／エス filed Critical エム・アンド・イー・バイオテク・エー／エス
Publication of JPH11505724A publication Critical patent/JPH11505724A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP8536119A 1995-06-02 1996-05-31 生物活性ペプチド及び核酸の同定方法 Ceased JPH11505724A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0629/95 1995-06-02
DK62995 1995-06-02
PCT/DK1996/000231 WO1996038553A1 (fr) 1995-06-02 1996-05-31 Procede d'identification de peptides et d'acides nucleiques biologiquement actifs

Publications (1)

Publication Number Publication Date
JPH11505724A true JPH11505724A (ja) 1999-05-25

Family

ID=8095753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8536119A Ceased JPH11505724A (ja) 1995-06-02 1996-05-31 生物活性ペプチド及び核酸の同定方法

Country Status (12)

Country Link
EP (2) EP0832207B1 (fr)
JP (1) JPH11505724A (fr)
KR (1) KR19990022157A (fr)
AT (1) ATE196312T1 (fr)
AU (1) AU699568B2 (fr)
CA (1) CA2222879A1 (fr)
DE (1) DE69610310T2 (fr)
DK (1) DK0832207T3 (fr)
ES (1) ES2151167T3 (fr)
GR (1) GR3035017T3 (fr)
PT (1) PT832207E (fr)
WO (1) WO1996038553A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503728A (ja) * 2021-01-19 2024-01-26 ホープ・パテンツ・エルエルシー 様々な状態を処置するためのペプチド治療薬を同定する方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6153380A (en) * 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
AU777489B2 (en) * 1996-01-23 2004-10-21 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6969584B2 (en) 1997-06-12 2005-11-29 Rigel Pharmaceuticals, Inc. Combinatorial enzymatic complexes
US6700040B2 (en) * 1998-01-16 2004-03-02 Large Scale Biology Corporation Cytoplasmic gene inhibition or gene expression in transfected plants by a tobraviral vector
DE69933856D1 (de) * 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US7005423B1 (en) 1999-07-02 2006-02-28 Devgen Nv Characterization of gene function using double stranded RNA inhibition
EP1270746A1 (fr) * 1998-07-20 2003-01-02 Inoxell A/S Methods pour l'identification de ligands et de biomolecules cibles
ATE223971T1 (de) * 1998-07-20 2002-09-15 Inoxell As Neue methoden zum auffinden von liganden- und ziel-biomolekülen
EP1109898A1 (fr) * 1998-09-04 2001-06-27 ZK Pharmaceuticals Inc. Technique de selection des peptides inhibant la liaison d'une proteine virale de surface a un recepteur de surface cellulaire
EP1041144B1 (fr) * 1999-03-29 2004-06-23 Michael Blind Procédé pour l'identification et la validation des cibles au moyen des intramers ou de la selection in vivo
AU2001289284A1 (en) * 2000-04-04 2001-10-15 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
JP2004530117A (ja) * 2001-02-22 2004-09-30 プラエシス ファーマシューティカルズ インコーポレーテッド 生物プロセスを調節するペプチドを同定する方法
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
EP2098536A1 (fr) * 2008-03-05 2009-09-09 4-Antibody AG Isolation et identification de protéines de liaison spécifiques à des antigènes ou à des ligands
WO2016138231A2 (fr) 2015-02-27 2016-09-01 Sauder Timothy Lee Commutateur bi-stable moléculaire à code à barres
US10620185B2 (en) 2015-02-27 2020-04-14 Aptascan, Inc. Molecular barcoded bi-stable switch
US11739370B1 (en) 2020-01-10 2023-08-29 Gordian Biotechnology, Inc. Methods and compositions for in vivo screening of therapeutics through spatial transcriptomics
EP4330406A4 (fr) * 2021-04-26 2025-03-05 Gordian Biotechnology, Inc. Compositions et procédés pour le criblage invivo de produits thérapeutiques utilisant le séquençage mononucléaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768377A1 (fr) * 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
WO1993003143A1 (fr) * 1991-08-07 1993-02-18 Anderson W French Vecteurs retroviraux contenant des sites internes d'entree de ribosome
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
WO1994018219A1 (fr) * 1993-02-02 1994-08-18 The Scripps Research Institute Procedes de production de banques d'anticorps utilisant des chaines legeres d'immunoglobulines universelles ou aleatoires
DE69434860T2 (de) * 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
WO1994020608A1 (fr) * 1993-03-12 1994-09-15 Creighton University Vecteurs ameliores en therapie genique
WO1995004824A1 (fr) * 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Production de banques d'adn et vecteurs retroviraux utilises a cet effet
WO1995011998A1 (fr) * 1993-10-26 1995-05-04 United Biomedical, Inc. Bibliotheques structurees d'antigenes de synthese utilisables a des fins de diagnostic, de vaccin et de therapie

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503728A (ja) * 2021-01-19 2024-01-26 ホープ・パテンツ・エルエルシー 様々な状態を処置するためのペプチド治療薬を同定する方法

Also Published As

Publication number Publication date
GR3035017T3 (en) 2001-03-30
EP0832207A1 (fr) 1998-04-01
DE69610310D1 (de) 2000-10-19
ES2151167T3 (es) 2000-12-16
KR19990022157A (ko) 1999-03-25
DK0832207T3 (da) 2000-11-06
AU5893396A (en) 1996-12-18
PT832207E (pt) 2001-03-30
ATE196312T1 (de) 2000-09-15
DE69610310T2 (de) 2001-03-15
EP0832207B1 (fr) 2000-09-13
AU699568B2 (en) 1998-12-10
EP1041143A2 (fr) 2000-10-04
CA2222879A1 (fr) 1996-12-05
EP1041143A3 (fr) 2000-11-29
WO1996038553A1 (fr) 1996-12-05

Similar Documents

Publication Publication Date Title
AU699568B2 (en) A method for identification of biologically active peptides and nucleic acids
Crawford et al. Mimotopes for alloreactive and conventional T cells in a peptide–MHC display library
US5843701A (en) Systematic polypeptide evolution by reverse translation
US20040110253A1 (en) Method for identifying MHC-presented peptide epitopes for T cells
US20030082719A1 (en) T cell receptor libraries
WO1992002536A1 (fr) Evolution polypeptidique systematique par traduction inverse
JPH0856667A (ja) 組換えｄｎａ技術によってｄｎａ、ｒｎａ、 ペプタイド、ポリペプタイド、または蛋白質 を取得するための方法
Goff et al. Mutants of murine leukemia viruses and retroviral replication
US20010034028A1 (en) Methods and compositions for elucidating relative protein expression levels in cells
US20030082514A1 (en) Method for identification of biologically active peptides and nucleic acids
US7625742B2 (en) Avian leukosis viruses and polypeptide display
JP4287633B2 (ja) オルガネラ局在タンパク質の解析方法と解析材料
Goff The genetics of murine leukemia viruses
US20210214722A1 (en) Methods and materials for cloning functional t cell receptors from single t cells
CA2403567A1 (fr) Procedes et compositions servant a identifier des profils d'expression de proteines dans des cellules
JP3994291B2 (ja) 抗体遺伝子発現ベクターのマルチコンビネーションライブラリの作製方法
US7186505B1 (en) Expression systems and methods for detecting and isolating polypeptides regulating signal transduction pathways
EP4646484A1 (fr) Procédés et systèmes de modification de cellules et de validation de cible
JP3994291B6 (ja) 抗体遺伝子発現ベクターのマルチコンビネーションライブラリの作製方法
EP1363931A2 (fr) Procedes de production et d'identification d'anticorps monoclonaux diriges contre un grand nombre d'antigenes humains
CN120936622A (zh) 抗体结合和特异性的高通量分析
Biro Design and Production of Specifically High Affinity Reacting Peptides (SHARP®-s)
WO1999007842A1 (fr) Materiel et methodes de selection de liants de ligands presentant un phage

Legal Events

Date Code Title Description
A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20040309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040330